BiotechTube

Alpha1-proteinase inhibitor

ApprovedCompleted
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Alpha1-proteinase Inhibitor Deficiency

Conditions

Alpha1-proteinase Inhibitor Deficiency, Emphysema

Trial Timeline

Mar 1, 2006 → Sep 1, 2012

NCT ID
NCT00261833

About Alpha1-proteinase inhibitor

Alpha1-proteinase inhibitor is a approved stage product being developed by CSL for Alpha1-proteinase Inhibitor Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00261833. Target conditions include Alpha1-proteinase Inhibitor Deficiency, Emphysema.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00261833ApprovedCompleted

Other Products from CSL

IgPro10Approved
84
four factor prothrombin complex concentrateApproved
84
Prothrombin complex concentrate (Human) + Fresh frozen plasma (FFP)Approved
84
IgPro10Approved
84
Blood coagulation Factor VIII and vWF, humanApproved
84